1 citations
,
December 2020 in “Dermatology Archives” This study found that pediatric patients with severe alopecia areata showed significant improvement with systemic corticosteroids but typically experienced relapse within 4-5 months, also seeing an increase in weight percentiles.
April 2026 in “Pediatric Dermatology” This review analyzes quality of life instruments for pediatric alopecia areata and reports inconsistencies in their coverage, suggesting the need for new tools to comprehensively assess all affected life aspects.
November 2025 in “Mendeley Data” This study found that tofacitinib and baricitinib, when administered with unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe AA, showed comparable efficacy and tolerability, though baricitinib's efficacy decreased with non-standard dosing.
January 2024 in “Dermatology practical & conceptual” This study found that topical immunotherapy was effective in 56.83% of pediatric patients with alopecia areata, but those with co-occurring atopic dermatitis were more likely to show an inadequate response to treatment.
July 2024 in “Journal of Investigative Dermatology” Pediatric patients with dystrophic epidermolysis bullosa face more hospital admissions, procedures, and complications than others.
